The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1539
January 29, 2018
View Complete Issue         Table of Contents 2019 
Neratinib (Nerlynx) for HER2-Positive Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Neratinib (Nerlynx) for HER2-Positive Breast Cancer
January 29, 2018 (Issue: 1539)
The FDA has approved the oral tyrosine kinase inhibitor neratinib (Nerlynx – Puma Biotechnology) for extended adjuvant treatment of adults with early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, following...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Neratinib (Nerlynx) for HER2-Positive Breast Cancer
Article code: 1539d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.